Display scaffolds: protein engineering for novel therapeutics

Current Opinion in Pharmacology

Volumn 8, Issue 5, 2008, Pages 609-615

  Nuttall, Stewart D ^a   Walsh, Renae B ^b  

^a CSIRO   (Australia)

^b VICTORIAN INFECTIOUS DISEASES REFERENCE LABORATORY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; CD23 ANTIGEN; CD8 ANTIGEN; CELL ADHESION MOLECULE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FIBRONECTIN; IMMUNOGLOBULIN HEAVY CHAIN; IMMUNOGLOBULIN LIGHT CHAIN; INTERLEUKIN 2 RECEPTOR; INTERLEUKIN 6; LIPOSOME; LYMPHOCYTE RECEPTOR; MONOCLONAL ANTIBODY; NANOCAPSULE; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; T LYMPHOCYTE RECEPTOR; TGN 1412; VASCULOTROPIN; VASCULOTROPIN RECEPTOR;

ANTIVIRAL ACTIVITY; BACILLUS ANTHRACIS; BACILLUS CEREUS; CLINICAL TRIAL; COMPLEMENTARITY DETERMINING REGION; DRUG ACCUMULATION; DRUG PENETRATION; DRUG TARGETING; EPSTEIN BARR VIRUS; HUMAN; LUNG NON SMALL CELL CANCER; MOLECULAR LIBRARY; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN ENGINEERING; REVIEW; SOLID TUMOR; VIRAL GENE DELIVERY SYSTEM;

ANIMALS; ANTIBODIES; CAMELS; HUMANS; IMMUNOGLOBULINS; LAMPREYS; PROTEIN ENGINEERING; RECOMBINANT PROTEINS;

EID: 54849406976     PISSN: 14714892     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.coph.2008.06.007     Document Type: Review

References (52)

1. Gill D.S., and Damle N.K. Biopharmaceutical drug discovery using novel protein scaffolds. Curr Opin Biotechnol 17 (2006) 653-658
2. Taussig M.J., Stoevesandt O., Borrebaeck C.A., Bradbury A.R., Cahill D., Cambillau C., de Daruvar A., Dubel S., Eichler J., Frank R., et al. Proteomebinders: planning a European resource of affinity reagents for analysis of the human proteome. Nat Methods 4 (2007) 13-17. Co-ordinated attempt by European consortium to establish an extensive resource of well-characterised affinity reagents. This article describes selection strategies and scaffold binders, with an emphasis on high throughput requirements for targets identified by analysis of the human proteome.
3. Skerra A. Alternative non-antibody scaffolds for molecular recognition. Curr Opin Biotechnol 18 (2007) 295-304
4. Kim S.J., Park Y., and Hong H.J. Antibody engineering for the development of therapeutic antibodies. Mol Cells 20 (2005) 17-29
5. Watt P.M. Screening for peptide drugs from the natural repertoire of biodiverse protein folds. Nat Biotechnol 24 (2006) 177-183
6. Binz H.K., Amstutz P., and Pluckthun A. Engineering novel binding proteins from nonimmunoglobulin domains. Nat Biotechnol 23 (2005) 1257-1268. Comprehensive scaffold review that, while published in 2005, is an ideal introduction to the diversity of alternative scaffolds and the rationale behind their design and study.
7. Hey T., Fiedler E., Rudolph R., and Fiedler M. Artificial, non-antibody binding proteins for pharmaceutical and industrial applications. Trends Biotechnol 23 (2005) 514-522
8. HH domains, and thus, could not have been identified by analysis of natural sequences and structures..."-a comment possibly with half an eye on the intellectual property landscape.
9. Villani M.E., Di Carli M., Donini M., Traversini G., Lico C., Franconi R., Benvenuto E., and Desiderio A. Validation of a stable recombinant antibodies repertoire for the direct selection of functional intracellular reagents. J Immunol Methods 329 (2008) 11-20
10. Qiu X.Q., Wang H., Cai B., Wang L.L., and Yue S.T. Small antibody mimetics comprising two complementarity-determining regions and a framework region for tumor targeting. Nat Biotechnol 25 (2007) 921-929. This article reports a novel approach to reduction of the antibody Fv, by linking CDRs from adjacent domains through a single framework region. Importantly, when linked to the toxin colicin Ia to produce 'pheromonicins' these constructs exhibited targeted inhibition of tumour growth. Questions remain, for example immunogenicity of such protein, but an innovative and promising approach.
11. Saerens D., Ghassabeh G.H., and Muyldermans S. Single-domain antibodies as building blocks for novel therapeutics. Current Opinions in Pharmacology 8 (2008) 600-608
12. Henderson K.A., Streltsov V.A., Coley A.M., Dolezal O., Hudson P.J., Batchelor A.H., Gupta A., Bai T., Murphy V.J., Anders R.F., et al. Structure of an IgNAR-AMA1 complex: targeting a conserved hydrophobic cleft broadens malarial strain recognition. Structure 15 (2007) 1452-1466
13. Baral T.N., Magez S., Stijlemans B., Conrath K., Vanhollebeke B., Pays E., Muyldermans S., and De Baetselier P. Experimental therapy of African trypanosomiasis with a nanobody-conjugated human trypanolytic factor. Nat Med 12 (2006) 580-584
14. Li Y., Moysey R., Molloy P.E., Vuidepot A.L., Mahon T., Baston E., Dunn S., Liddy N., Jacob J., Jakobsen B.K., et al. Directed evolution of human T-cell receptors with picomolar affinities by phage display. Nat Biotechnol 23 (2005) 349-354
15. Zhao Y., Bennett A.D., Zheng Z., Wang Q.J., Robbins P.F., Yu L.Y., Li Y., Molloy P.E., Dunn S.M., Jakobsen B.K., et al. High-affinity TCRs generated by phage display provide CD4+ T cells with the ability to recognize and kill tumor cell lines. J Immunol 179 (2007) 5845-5854
16. Streltsov V.A., Varghese J.N., Carmichael J.A., Irving R.A., Hudson P.J., and Nuttall S.D. Structural evidence for evolution of shark Ig new antigen receptor variable domain antibodies from a cell-surface receptor. Proc Natl Acad Sci U S A 101 (2004) 12444-12449
17. Lipovsek D., Lippow S.M., Hackel B.J., Gregson M.W., Cheng P., Kapila A., and Wittrup K.D. Evolution of an interloop disulfide bond in high-affinity antibody mimics based on fibronectin type III domain and selected by yeast surface display: molecular convergence with single-domain camelid and shark antibodies. J Mol Biol 368 (2007) 1024-1041
18. Koide A., Gilbreth R.N., Esaki K., Tereshko V., and Koide S. High-affinity single-domain binding proteins with a binary-code interface. Proc Natl Acad Sci U S A 104 (2007) 6632-6637. Tyrosine residues are traditionally over-represented in antibody paratopes. This study asks whether binding-loops comprised only tyrosine and serine residues can generate sufficient conformational and interface diversity to effectively target antigen. The authors answer in the positive, and present a 'monobody'-maltose-binding protein co-crystallographic structure which shows dominant contributions of tyrosine residues and molecular mimicry of β-cyclodextrin, an MBP substrate. Food for thought for the molecular library generation community!
19. Simonsen S.M., Sando L., Rosengren K.J., Wang C.K., Colgrave M.L., Daly N.L., and Craik D.J. Alanine scanning mutagenesis of the prototypic cyclotide reveals a cluster of residues essential for bioactivity. J Biol Chem 283 (2008) 9805-9813
20. Cortajarena A.L., Yi F., and Regan L. Designed TPR modules as novel anticancer agents. ACS Chem Biol 3 (2008) 161-166
21. Seelig B., and Szostak J.W. Selection and evolution of enzymes from a partially randomized non-catalytic scaffold. Nature 448 (2007) 828-831. Another excellent paper from one of the pioneers in the protein display field. Selection technologies have always been a necessary component of any scaffold design system, and here the authors harness the combinatorial power of ribosome display in combination with a dual zinc finger-based scaffold library, to derive novel proteins that both bound their target and catalysed an RNA ligase enzymatic reaction.
22. Parmeggiani F., Pellarin R., Larsen A.P., Varadamsetty G., Stumpp M.T., Zerbe O., Caflisch A., and Pluckthun A. Designed armadillo repeat proteins as general peptide-binding scaffolds: consensus design and computational optimization of the hydrophobic core. J Mol Biol 376 (2008) 1282-1304. This laboratory has been at the forefront of scaffold design and selection system development for the past two decades. Libraries of this scaffold will be focussed squarely on isolation of peptide-specific binders.
23. Merz T., Wetzel S.K., Firbank S., Pluckthun A., Grutter M.G., and Mittl P.R. Stabilizing ionic interactions in a full-consensus ankyrin repeat protein. J Mol Biol 376 (2008) 232-240
24. •]. It will be interesting to compare in vitro selection on the basis of large engineered VLR libraries, with in vivo selection from lamprey immunisation. Such comparative experiments have only been possible to date in immunoglobulin-based antibody systems (murine, camel and shark). It will be a true test of the ability of protein engineering to mimic in vivo selection in the alternative scaffold space, especially as VLRs are modular and amenable to affinity maturation through module shuffling as well as point mutation.
25. Alder M.N., Herrin B.R., Sadlonova A., Stockard C.R., Grizzle W.E., Gartland L.A., Gartland G.L., Boydston J.A., Turnbough Jr. C.L., and Cooper M.D. Antibody responses of variable lymphocyte receptors in the lamprey. Nat Immunol 9 (2008) 319-327. After decades of searching for immunoglobulin-based antibodies in lampreys, it now appears that the adaptive arm of the immune response in these animals is mediated by modular leucine-rich repeat units.
26. Sheridan C. Pharma consolidates its grip on post-antibody landscape. Nat Biotechnol 25 (2007) 365-366. Read this for an introduction to commercial interests operating in the scaffold space. See also reference [3].
27. Getmanova E.V., Chen Y., Bloom L., Gokemeijer J., Shamah S., Warikoo V., Wang J., Ling V., and Sun L. Antagonists to human and mouse vascular endothelial growth factor receptor 2 generated by directed protein evolution in vitro. Chem Biol 13 (2006) 549-556
28. Silverman J., Liu Q., Bakker A., To W., Duguay A., Alba B.M., Smith R., Rivas A., Li P., Le H., et al. Multivalent avimer proteins evolved by exon shuffling of a family of human receptor domains. Nat Biotechnol 23 (2005) 1556-1561
29. Friedman M., Nordberg E., Hoiden-Guthenberg I., Brismar H., Adams G.P., Nilsson F.Y., Carlsson J., and Stahl S. Phage display selection of Affibody molecules with specific binding to the extracellular domain of the epidermal growth factor receptor. Protein Eng Des Sel 20 (2007) 189-199
30. Hoyer W., Gronwall C., Jonsson A., Stahl S., and Hard T. Stabilization of a β-hairpin in monomeric Alzheimer's amyloid- β peptide inhibits amyloid formation. Proc Natl Acad Sci U S A (2008)
31. Gronwall C., Snelders E., Jarelov Palm A., Eriksson F., Herne N., and Stahl S. Generation of Affibody ligands binding the IL-2 receptor alpha. Biotechnol Appl Biochem 50 (2008) 97-112
32. Kramer-Marek G., Kiesewetter D.O., Martiniova L., Jagoda E., Lee S.B., and Capala J. [(18)F]FBEM-Z(HER2:342) - Affibody molecule - a new molecular tracer for in vivo monitoring of HER2 expression by positron emission tomography. Eur J Nucl Med Mol Imaging 35 (2008) 1008-1018
33. Tolmachev V., Orlova A., Pehrson R., Galli J., Baastrup B., Andersson K., Sandstrom M., Rosik D., Carlsson J., Lundqvist H., et al. Radionuclide therapy of HER2-positive microxenografts using a 177Lu-labeled HER2-specific Affibody molecule. Cancer Res 67 (2007) 2773-2782
34. Fortin M.A., Orlova A., Malmstrom P.U., and Tolmachev V. Labelling chemistry and characterization of [90Y/177Lu]-DOTA-ZHER2:342-3 Affibody molecule, a candidate agent for locoregional treatment of urinary bladder carcinoma. Int J Mol Med 19 (2007) 285-291
35. Tran T., Orlova A., Sivaev I., Sandstrom M., and Tolmachev V. Comparison of benzoate- and dodecaborate-based linkers for attachment of radioiodine to HER2-targeting affibody ligand. Int J Mol Med 19 (2007) 485-493
36. Belousova N., Mikheeva G., Gelovani J., and Krasnykh V. Modification of adenovirus capsid with a designed protein ligand yields a gene vector targeted to a major molecular marker of cancer. J Virol 82 (2008) 630-637
37. Zahnd C., Wyler E., Schwenk J.M., Steiner D., Lawrence M.C., McKern N.M., Pecorari F., Ward C.W., Joos T.O., and Pluckthun A. A designed ankyrin repeat protein evolved to picomolar affinity to Her2. J Mol Biol 369 (2007) 1015-1028
38. Schweizer A., Roschitzki-Voser H., Amstutz P., Briand C., Gulotti-Georgieva M., Prenosil E., Binz H.K., Capitani G., Baici A., Pluckthun A., et al. Inhibition of caspase-2 by a designed ankyrin repeat protein: specificity, structure, and inhibition mechanism. Structure 15 (2007) 625-636
39. Skerra A. Anticalins as alternative binding proteins for therapeutic use. Curr Opin Mol Ther 9 (2007) 336-344
40. Bai J., Sui J., Zhu R.Y., Tallarico A.S., Gennari F., Zhang D., and Marasco W.A. Inhibition of Tat-mediated transactivation and HIV-1 replication by human anti-hCyclinT1 intrabodies. J Biol Chem 278 (2003) 1433-1442
41. Lynch S.M., Zhou C., and Messer A. An scFv intrabody against the nonamyloid component of alpha-synuclein reduces intracellular aggregation and toxicity. J Mol Biol 377 (2008) 136-147
42. Cardinale A., Filesi I., Vetrugno V., Pocchiari M., Sy M.S., and Biocca S. Trapping prion protein in the endoplasmic reticulum impairs PrPC maturation and prevents PrPSc accumulation. J Biol Chem 280 (2005) 685-694
43. Melchionna T., and Cattaneo A. A protein silencing switch by ligand-induced proteasome-targeting intrabodies. J Mol Biol 374 (2007) 641-654
44. Manikandan J., Pushparaj P.N., and Melendez A.J. Protein i: interference at protein level by intrabodies. Front Biosci 12 (2007) 1344-1352. The authors explore the function of intrabodies and the concept of protein interference (protein i), presenting a comprehensive overview of intrabody development and selection technologies. They review current intrabodies, their therapeutic applications and the limitations and challenges affecting intrabody delivery.
45. Boldicke T. Blocking translocation of cell surface molecules from the ER to the cell surface by intracellular antibodies targeted to the ER. J Cell Mol Med 11 (2007) 54-70. This article explores the function of intracellular antibodies that inhibit target protein function through retention in the endoplasmic reticulum and explains the ER processing and degradation cycle. The author has collated a comprehensive list of therapeutic intrabodies utilising ER retention function and discusses the development of intrabodies in terms of delivery mechanisms and functionality in vivo.
46. Heng B.C., and Cao T. Making cell-permeable antibodies (transbody) through fusion of protein transduction domains (PTD) with single chain variable fragment (scFv) antibodies: potential advantages over antibodies expressed within the intracellular environment (intrabody). Med Hypotheses 64 (2005) 1105-1108
47. St Clair E.W. The calm after the cytokine storm: lessons from the TGN1412 trial. J Clin Invest (2008)
48. Dowsing T., and Kendall M.J. The Northwick Park tragedy-protecting healthy volunteers in future first-in-man trials. J Clin Pharm Ther 32 (2007) 203-207. An excellent description of what went wrong during the TGN1412 clinical trials, and safeguards being developed to prevent a recurrence. Sobering analysis that will leave researchers asking whether their protein scaffold or immunotherapeutic has a novel mode of action and capacity to modify the body's immune system.
49. De Groot A.S., and Moise L. Prediction of immunogenicity for therapeutic proteins: state of the art. Curr Opin Drug Discov Devel 10 (2007) 332-340
50. Casadevall A. Passive antibody administration (immediate immunity) as a specific defense against biological weapons. Emerg Infect Dis 8 (2002) 833-841
51. Dolk E., van der Vaart M., Lutje Hulsik D., Vriend G., de Haard H., Spinelli S., Cambillau C., Frenken L., and Verrips T. Isolation of llama antibody fragments for prevention of dandruff by phage display in shampoo. Appl Environ Microbiol 71 (2005) 442-450
52. DeLano W.L. The PyMOL Molecular Graphics System (2002), DeLano Scientific, Palo Alto, CA, USA